Meyka Pro banner
Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) AI-Powered Stock Analysis

See how Anbio Biotechnology Class A Ordinary Shares scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

NNNNNASDAQ
HealthcareMedical - Instruments & Supplies
$9.90
$0.16(1.64%)
U.S. Market opens in 14h 25m

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) AI-Powered Stock Analysis

See how Anbio Biotechnology Class A Ordinary Shares scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) Stock Overall Grade

Anbio Biotechnology Class A Ordinary Shares's grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

Z

Grade Breakdown by Metric

See how each financial and market factor contributes to Anbio Biotechnology Class A Ordinary Shares's overall NASDAQ stock rating.

Forecast

A

Score

86/100

Financial Growth

A

Score

80/100

Fundamental Growth

A+

Score

90/100

Key Ratios

B+

Score

72/100

Sector Comparison

B+

Score

75/100

Industry Comparison

C+

Score

50/100

S&P 500 Benchmark

A+

Score

97/100

Analyst Consensus

C+

Score

50/100

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) AI-Powered Stock Analysis

On the NASDAQ, NNNN demonstrates Good performance with an overall Forecast Score of 86/100 (A), reflecting high confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (90/100, A+) highlight its stability, while Key Ratios (72/100, B+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.

(NASDAQ: NNNN) Component Analysis Explained

Understand the key factors behind each Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions